PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine (Q45006316)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

title

PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

main subject

antibody

1 reference

based on heuristic

inferred from title

author name string

Randall Dere

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Joo-Hee Yi

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Corinna Lei

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Ola M Saad

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Catherine Huang

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Yanhong Li

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Jakub Baudys

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

Surinder Kaur

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

publication date

1 May 2013

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

published in

Bioanalysis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

volume

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

issue

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

page(s)

1025-1040

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

cites work

Antibody-drug conjugates for cancer therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Antibody targeted drugs as cancer therapeutics

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Arming antibodies for cancer therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Antibody-drug conjugates: targeted drug delivery for cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Untangling the ErbB signalling network

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Enzyme-linked immunosorbent assay (ELISA) quantitative assay of immunoglobulin G

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.4155%2FBIO.13.72

retrieved

21 January 2018

Identifiers

DOI

10.4155/BIO.13.72

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

PubMed publication ID

23641694

1 reference

stated in

Europe PubMed Central

PubMed publication ID

23641694

retrieved

8 December 2017

ResearchGate publication ID

236635811

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45006316&oldid=2061628412"